An Introduction to Gynaecological Oncology
The treatment landscape for gynaecological cancers, especially ovarian cancer, has evolved over recent years. Late diagnosis means ovarian cancer is often detected at an advanced stage, but the introduction of targeted therapies and immunotherapies have widened the treatment landscape. Cervical cancer has a high survival rate if detected early, and therefore screening continues to be an important issue.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes, view our expert-led learning activities.”
Gynaecological Oncology Content
High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy
touchREVIEWS in Oncology & Haematology. 2021;17(1):23-27 DOI: https://doi.org/10.17925/OHR.2021.17.1.23
Endometrial cancer has become an increasingly significant cause of morbidity and mortality for women. Currently, endometrial cancer is the most common invasive gynaecologic malignancy, and the ninth most common cancer among women in the USA, accounting for approximately 65,620 new cancer cases and 12,590 deaths in 2020.1 The 5-year relative survival rate is estimated to be […]
Linda Mileshkin, ESMO 2019 – Phase III OUTBACK trial in cervical cancer
We joined Linda Mileshkin (Peter MacCallum Cancer Centre) following her presentation at ESMO 2019 to discuss the disparities of starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial. Questions 1. Could you tell us a little about the OUTBACK trial and its findings? (0:06) 2. What was […]
Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors
European Oncology & Haematology. 2019;15(1):29–40 DOI: https://doi.org/10.17925/EOH.2019.15.1.29
Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]
Gloria Huang, ASCO 2019 – NRG Oncology/Gynecologic Oncology Group 210 trial
Gloria Huang discusses results from the NRG Oncology/Gynecologic Oncology Group 210 trial at the ASCO 2019 annual meeting. The trial investigates sex hormone, insulin and insulin-like growth factor signaling in the recurrence of high stage endometrial cancer. Questions 1. What is known about the role of sex hormone, insulin and insulin-like growth factor (IGF) axis […]
Advances in the Treatment of Endometrial and Ovarian Cancer
Oncology & Hematology Review. 2019;15(1):23–4 DOI: https://doi.org/10.17925/OHR.2019.15.1.23
Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, resulting in a 5-year overall survival rate of only 20–30%. However, survival at all […]
Olaparib as a Maintenance Therapy for Ovarian Cancer and its use in BRCA-related Metastatic Breast Cancer
Recent results from trials with olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, are discussed in this Insight. Positive data and regulatory approvals are demonstrating that targeting the underlying genetic causes of a cancer can be a powerful tool for the development of new treatments with efficacy across different cancer types.
The Belarus Experience of Pelvic Artery Embolisation in Patients with Advanced and Recurrent Cervical Cancer Presenting with Haemorrhage
European Oncology & Haematology, 2018;14(1):45–49 DOI: https://doi.org/10.17925/EOH.2018.14.1.45
Cervical cancer (CC) is a leading cause of cancer morbidity in women globally. In Europe, epidemiological data on CC incidence shows important differences between countries: from 3.6 per 100,000 women in Switzerland to 28.6 per 100,000 in Romania.1,2 In 2015 in the Republic of Belarus, the morbidity and mortality rate from CC were 11.9 and […]
Adenocarcinoma in situ of the Cervix – is Loop Electrosurgical Excision Procedure an Acceptable Alternative to Cold Knife Cone Biopsy?
European Oncology & Haematology, 2017;13(1):24–7 DOI: https://doi.org/10.17925/EOH.2017.13.01.24
Cervical adenocarcinoma in situ (AIS) is recognised as a premalignant glandular condition and is a precursor to invasive cervical adenocarcinoma.1 It usually affects women of childbearing age in which a more conservative approach is preferred.1–3 The incidence of both AIS and adenocarcinoma of the cervix has been increasing, especially among young women.4,5 Cervical conisation, or […]
Bevacizumab in the Treatment of Cervical Cancer – Current Evidence and Next Steps
European Oncology & Haematology, 2016;12(1):32–43 DOI: https://doi.org/10.17925/EOH.2016.12.01.32
Worldwide, cervical cancer is the fourth most common cancer in women and seventh most common cancer overall. In 2012, approximately 528,000 new cervical cancer cases were diagnosed globally. Cervical cancer accounted for 7.5% of all female cancer deaths with approximately 266,000 deaths; the majority (87%) of these deaths occurred in developing countries.1,2 In Europe, the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!